Chemistry and Industry - Crestor takes heart.(Letters)(Letter to the editor)
The METEOR trial examined AstraZeneca’s Crestor (rosuvastatin) in patients with early signs of atherosclerosis. C&I notes that because the METEOR study did not show regression of atherosclerosis, it ‘dashes hopes for an expanded label’ (C&I 2007, 7, 7). While METEOR did not show regression, this was not its primary endpoint.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
METEOR was designed to see if Crestor could halt the progression of atherosclerosis in patients at low-risk for coronary heart disease with early signs of atherosclerosis as determined by an increased carotid intima-media thickness. The study met its …
Read the rest of this article with a Free Trial at HighBeam Research.
